Highlights                                                                                                                                       

  • Argenica Therapeutics shares jumped 9.09% to AUD 0.12 during the afternoon session on 11 June 2026.
  • ARG-007 (xaranetide) successfully completed the third and final FDA-requested safety assay.
  • The GLP-compliant hERG assay showed no statistically significant inhibition of the hERG cardiac potassium channel.
  • All three FDA-requested safety studies have now been completed with favourable outcomes.
  • The company expects to submit a comprehensive response to the FDA clinical hold following finalisation of its Phase 2b protocol.

Argenica Therapeutics Ltd (ASX:AGN) shares climbed 9.09% to AUD 0.12 during the afternoon session on 11 June 2026 after the biotechnology company announced that its lead drug candidate, ARG-007 (xaranetide), had successfully completed the final safety study requested by the U.S. Food and Drug Administration (FDA).

The announcement represents a significant regulatory milestone for the company, as all three studies required by the FDA under its clinical hold process have now been completed. Investors appeared to respond positively to the update, which strengthens Argenica’s position ahead of a planned submission seeking removal of the FDA clinical hold and progression into Phase 2b clinical development.

Although the company’s shares remain down 83.33% over the past year, the latest development marks a potentially important step in the advancement of ARG-007, which is being developed to reduce brain tissue damage following stroke and other acute neurological conditions.

Final FDA-Requested Safety Study Delivers Positive Outcome

The key announcement centred on the successful completion of a Good Laboratory Practice (GLP)-compliant hERG assay, the third and final study requested by the FDA.

According to Argenica, the study demonstrated that ARG-007 does not significantly inhibit the hERG cardiac potassium channel, one of the most important safety markers evaluated during drug development.

The company reported that the assay showed no statistically significant inhibition of the channel at the highest testable concentration, supporting what management described as a favourable cardiac safety profile for the drug candidate.

Completion of the hERG study removes the final outstanding assay requirement identified by the FDA as part of its clinical hold review process.

The company had previously completed the other two requested studies, namely the TNK assay and the genotoxicity assay.

With all three safety assessments now completed, Argenica believes it is in a position to prepare a comprehensive response to the regulator.

Why the hERG Assay Matters

The hERG potassium channel plays a critical role in regulating electrical activity within the heart.

Historically, inhibition of this channel has been associated with potentially serious cardiac side effects, including dangerous arrhythmias and, in some cases, sudden cardiac death.

Because of these risks, regulatory agencies place significant emphasis on hERG testing during the drug development process.

Several pharmaceutical compounds have previously faced restrictions or market withdrawals due to hERG-related cardiac safety concerns.

As a result, demonstrating minimal interaction with the hERG channel is considered an important milestone when evaluating the safety profile of investigational therapies.

Argenica noted that the absence of meaningful hERG inhibition supports a favourable cardiac safety profile for ARG-007.

The company believes this outcome directly addresses the FDA's previously identified concerns regarding cardiac safety data.

Study Results Highlight Favourable Cardiac Safety Profile

The hERG study was conducted by Switzerland-based safety pharmacology specialist B'SYS GmbH under GLP conditions.

Testing was performed using the whole-cell patch-clamp technique on Chinese Hamster Ovary (CHO) cells engineered to express the hERG channel under near-physiological temperatures, consistent with international regulatory guidelines.

At the highest testable concentration of 1 microgram per millilitre, ARG-007 demonstrated a remaining hERG current amplitude of 100.74% ± 1.44%.

According to the company, this result effectively represents full preservation of baseline cardiac channel activity.

Statistical analysis showed that the outcome was not significantly different from the vehicle control group, which recorded a remaining current amplitude of 96.48% ± 1.02%.

The reported p-value of 0.0524 exceeded the statistical significance threshold, supporting the conclusion that ARG-007 did not meaningfully inhibit the channel.

Importantly, because channel inhibition remained well below 30% even at the highest testable concentration, researchers were unable to calculate an IC50 value.

This indicates that the concentration required to produce meaningful hERG channel inhibition lies beyond the measurable range of the assay.

The company described this as an exceptionally favourable result.

Positive Controls Confirm Assay Reliability

The study also incorporated a positive control compound to validate the performance of the testing system.

Moxifloxacin, a compound with known hERG-related pharmacological activity, was used as the positive control.

According to Argenica, Moxifloxacin produced the anticipated concentration-dependent inhibition of the hERG channel.

At a concentration of 30 micromolar, the compound generated a remaining current amplitude of 73.14% ± 2.07%.

At 150 micromolar, the remaining current amplitude declined further to 38.87% ± 2.56%.

The company stated that these results demonstrated the sensitivity and reliability of the assay system and confirmed the validity of the study outcomes.

Background to the FDA Clinical Hold

The latest announcement stems from a clinical hold issued by the FDA regarding Argenica’s Investigational New Drug (IND) application for ARG-007.

The regulator previously advised that there was insufficient information available to fully assess risks to human subjects and requested additional in vitro safety data before allowing clinical progression.

Three specific studies were identified as necessary to address the FDA’s concerns.

These included the TNK assay, the genotoxicity assay and the GLP-compliant hERG study.

The company has now completed all three assessments.

Management stated that each of the studies produced favourable safety outcomes, allowing Argenica to move toward the next stage of the regulatory process.

Pathway Toward Phase 2b Clinical Development

With the final safety study completed, Argenica is now focused on preparing its formal response to the FDA.

The company indicated that finalisation of the Phase 2b clinical protocol is expected in the coming weeks.

Once completed, Argenica intends to compile a comprehensive submission addressing all issues raised by the regulator.

The response package is expected to include the completed safety studies, updates to the investigational brochure and a revised Phase 2b trial design focused on moderate-to-severe stroke patients.

Management stated that the company aims to submit the response in the coming weeks.

If accepted by the FDA, the clinical hold would be lifted and the IND reinstated, enabling clinical studies involving U.S. patients to proceed.

About ARG-007 and Argenica's Development Strategy

Argenica is a clinical-stage biotechnology company focused on developing treatments for acute neurological conditions.

Its lead drug candidate, ARG-007 (xaranetide), is designed to protect vulnerable brain tissue following stroke and other neurological injuries.

The therapy aims to reduce cell death and minimise secondary damage that occurs after an ischemic event.

The company believes this approach could potentially improve patient outcomes and recovery following stroke.

Current development activities are centred on advancing ARG-007 through clinical evaluation and securing the regulatory approvals necessary to support future trials.

The successful completion of the FDA-requested safety program forms an important component of that strategy.

Regulatory Progress Represents a Key Milestone

For biotechnology companies, regulatory progress often plays a significant role in determining development timelines.

The completion of all FDA-requested studies removes an important procedural hurdle and provides the company with the data required to respond comprehensively to the regulator's concerns.

Although FDA review outcomes remain subject to regulatory assessment, Argenica has now completed each of the specific studies identified within the clinical hold process.

The company believes this positions it to move forward with the next stage of regulatory engagement.

Future investor attention is likely to focus on the FDA submission process and any subsequent updates regarding the clinical hold status.

What This Means for Investors

Argenica’s latest announcement represents a significant regulatory milestone for its lead drug candidate, ARG-007. The company has now completed all three safety studies requested by the FDA, including the final GLP-compliant hERG assay, which demonstrated no statistically significant inhibition of the hERG cardiac potassium channel.

The positive share price reaction on 11 June 2026 suggests investors welcomed the completion of the final outstanding safety requirement. Going forward, market attention is likely to centre on the finalisation of the Phase 2b protocol, submission of the FDA response package and any regulatory decisions relating to the lifting of the clinical hold and reinstatement of the Investigational New Drug application.